# Molecular Cancer Therapeutics

## Table of Contents

### April 2015 • Volume 14 • Number 4

### Highlights of This Issue 845

### REVIEW

**847**  
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy  
Sandip Pravin Patel and Razelle Kurzrock

### SMALL MOLECULE THERAPEUTICS

**857**  
Preclinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas  
Nimita Dave, Lionel M.L. Chow, Gary A. Gudelsky, Kathleen LaSance, Xiaoyang Qi, and Pankaj B. Desai

**865**  
Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways  
Marieke Aarts, Ilirjana Bajrami, Maria T. Herrera-Abreu, Richard Elliott, Rachel Brough, Alan Ashworth, Christopher J. Lord, and Nicholas C. Turner

**877**  
ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells  
Shu Wang, Xiangyun Amy Chen, Jing Hu, Jian-kang Jiang, Yunfei Li, Ka Yim Chan-Salis, Ying Gu, Gong Chen, Craig Thomas, B. Franklin Pugh, and Yanming Wang

**889**  
The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias  
Maria Vittoria Verga Falzappa, Chiara Ronchini, Mario Fareta, Ilaria Iacobucci, Andrea Ghelli Lusena Di Rorà, Giovanni Martinelli, Liudrun Hinrich Meyer, Klaus-Michael Debatin, Stefania Orecchioni, Francesco Bertolini, and Pier Giuseppe Pellici

**899**  
Magnetic Resonance Spectroscopy for Detection of Choline Kinase Inhibition in the Treatment of Brain Tumors  
Manoj Kumar, Sean P. Areluckas, Sona Sakseva, Gaurav Verma, Ranjit Ittyerah, Stephen Pickup, Anatoliy V. Popov, Edward J. Delikatny, and Harish Poptani

### LARGE MOLECULE THERAPEUTICS

**909**  
IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment  

**920**  
Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer  

**931**  
The Selective P13K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models  

**941**  
New Blocking Antibodies against Novel AGR2–C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice  
Thiruvengadam Arumugam, Deleng Deng, Laura Bover, Huamin Wang, Craig D. Logsdon, and Vijaya Ramachandran

---

*Table of Contents (cont.)*
Polymorphic CAG Repeat and Protein Expression of Androgen Receptor Gene in Colorectal Cancer

Rui Huang, Guiyu Wang, Yanni Song, Feng Wang, Bing Zhu, Qinghao Tang, Zheng Liu, Yinggang Chen, Qian Zhang, Shan Muhammad, and Xishan Wang

MODELS AND TECHNOLOGIES

Multifunctional Polymeric Micelles Co-loaded with Anti–Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer

Giuseppina Salzano, Gemma Navarro, Malav S. Trivedi, Giuseppe De Rosa, and Vladimir P. Torchilin

ABOUT THE COVER

Deregulation of cell-cycle checkpoints is a feature of many different cancer types. WEE1 kinase plays an important role in the maintenance of these cell-cycle checkpoints by inhibiting cyclin-dependent kinase (CDK) activity. Through siRNA screening, it was found that cancer cells with defects in Fanconi Anemia (FA) and homologous recombination pathways were more sensitive to WEE1 inhibition. The cover image shows that WEE1 inhibition in cells depleted of FA protein FANCM resulted in increased replication stress (pan-nuclear γH2AX staining in green) and premature entry into mitosis (yellow). Phospho-histone H3 staining (red) was used to identify mitotic cells. DNA was counterstained with DAPI (blue). For details, see the article by Aarts and colleagues on page 865.